



International Journal of Homoeopathic Sciences

E-ISSN: 2616-4493
P-ISSN: 2616-4485
Impact Factor (RJIF): 5.96
www.homoeopathicjournal.com
IJHS 2025; 9(3): 1004-1008
Received: 14-06-2025
Accepted: 16-07-2025

Dr. Saroja Pujari
Internee of BVVS
Homoeopathic Medical College
and Hospital, Bagalkot,
Karnataka, India

Dr. Amaresh Balaganur
MD HOM
HOD of Department of
Practices of Medicines BVVS
Homoeopathic Medical College
and Hospital, Bagalkot,
Karnataka, India

Dr. Arun Hooli
MD HOM
Principal of BVVS
Homoeopathic Medical College
and Hospital, Bagalkot,
Karnataka, India

Corresponding Author:
Dr. Saroja Pujari
Internee of BVVS
Homoeopathic Medical College
and Hospital, Bagalkot,
Karnataka, India

Comparative role of *Formica rufa* and other homoeopathic medicines in menopausal osteoarthritis

Saroja Pujari, Amaresh Balaganur and Arun Hooli

DOI: <https://www.doi.org/10.33545/26164485.2025.v9.i3.P.1777>

Abstract

Background: Osteoarthritis (OA) is a prevalent degenerative joint disorder among menopausal women, primarily due to hormonal changes and decreased estrogen levels. Homoeopathic medicines are considered safe alternatives for managing pain, stiffness, and reduced mobility.

Objective: To evaluate and compare the effectiveness of *Formica rufa* with other homoeopathic medicines in menopausal women with osteoarthritis.

Methods: A comparative clinical study was conducted on menopausal women diagnosed with OA. Participants were divided into groups, one receiving *Formica rufa* and the others treated with indicated medicines (*Rhus tox*, *Calcarea fluorica*, *Ruta graveolens*, *Bryonia alba*, and *Causticum*). Symptom relief was assessed using the WOMAC index and VAS scale during the treatment period.

Results: Both *Formica rufa* and other medicines provided significant improvement in pain, stiffness, and mobility. However Individualized medicines showed superior results in reducing stiffness and improving joint function in menopausal cases.

Conclusion: *Formica rufa* demonstrates comparatively efficacy in managing menopausal osteoarthritis but individualized medicines show more in recovery. Homoeopathy offers a safe and effective approach, warranting further large-scale studies.

Keywords: *Formica rufa*, menopausal osteoarthritis, homoeopathy, degenerative joint disease, *Rhus toxicodendron*, *Calcarea fluorica*, *Ruta graveolens*, *Bryonia alba*, *causticum*

Introduction

Osteoarthritis is a progressive musculoskeletal condition characterized by chronic degenerative disease of articular cartilage breakdown, osteophyte formation, reduced joint space, joint stiffness, crepitus, and functional limitation. It is the leading cause of disability among menopausal women, the decline in estrogen (Hormonal change) accelerates joint wear-and-tear and predisposes to osteoporosis, making OA a major health burden.

Homoeopathy offers a holistic approach based on the principle of individualization. Medicines are selected not only on pathological findings but also on the characteristic modalities, mental state, and constitutional tendencies. Among these, the *Formica rufa* has been highlighted in rheumatic and arthritic cases.

This paper focuses on the role of *Formica rufa* in menopausal OA and its comparison with other indicated remedies.

Definition

Osteoarthritis (OA) is a chronic degenerative joint disorder characterized by the progressive loss of articular cartilage, changes in the underlying subchondral bone, formation of osteophytes (bony outgrowths), and varying degrees of synovial inflammation. It leads to joint pain, stiffness, swelling, reduced mobility, and functional impairment.

It is the most common type of arthritis, primarily affecting weight-bearing joints such as the knees, hips, and spine, though it can also occur in the hands and other joints.

Causes / Risk Factors of Osteoarthritis (ACR)

1. Age

Advancing age is the strongest risk factor; incidence increases significantly after 50 years, especially in women.

2. Sex/hormonal factors

More common in women, particularly after menopause, due to estrogen deficiency.

3. Genetic predisposition

Family history and genetic factors influence cartilage metabolism and susceptibility.

4. Obesity

Increases mechanical stress on weight-bearing joints (knee, hip) and contributes to metabolic inflammation.

5. Joint injury & overuse

Prior trauma, repetitive stress, or occupational strain accelerates degeneration.

6. Anatomical/mechanical factors

Malalignment of joints, congenital or developmental abnormalities (e.g., hip dysplasia), and abnormal biomechanics.

7. Metabolic/biochemical factors

Diabetes, metabolic syndrome, and other systemic conditions can contribute to cartilage degeneration.

8. Other contributing factors

Muscle weakness, poor proprioception, inflammatory mediators, and vascular changes in subchondral bone.

Pathogenesis of osteoarthritis (According to ACR)

Osteoarthritis develops as a result of complex mechanical, biochemical, and cellular processes that progressively damage articular cartilage, subchondral bone, and surrounding joint structures.

Step-wise pathogenesis

1. Initiating factors (Risk triggers)

Aging, obesity, trauma, repetitive joint stress, congenital deformities, or genetic predisposition.

These factors disrupt the balance between cartilage matrix synthesis and degradation.

2. Cartilage matrix changes

Chondrocytes respond to mechanical stress by increasing production of degradative enzymes (matrix metalloproteinases - MMPs).

Loss of proteoglycans and type II collagen weakens cartilage.

Water content of cartilage increases → reduced elasticity.

3. Cartilage breakdown

Fissuring, softening, and thinning of articular cartilage occur.

Chondrocytes undergo apoptosis, reducing their repair capacity.

4. Subchondral bone changes

Bone remodeling occurs beneath the damaged cartilage.

Subchondral sclerosis (hardening of bone) develops.

Formation of osteophytes (bony outgrowths) at joint margins.

Bone marrow lesions may develop due to microfractures.

5. Synovial inflammation (Secondary)

Mild, low-grade synovitis occurs due to release of cartilage and bone debris into the joint.

Synovium produces inflammatory cytokines (IL-1, TNF- α) that further stimulate cartilage breakdown.

6. Joint space narrowing

Progressive cartilage loss leads to narrowing of the joint space.

Joint movement becomes painful and restricted.

7. Clinical manifestations

Pain, stiffness (especially after rest), crepitus, swelling, reduced mobility, and deformity.

Miasmatic background

Homoeopathically, Osteoarthritis in menopausal women is understood as a chronic miasmatic expression, where hormonal decline (mainly estrogen deficiency) interacts with inherited and acquired miasms.

1. Psoric manifestations

Functional disturbances more than structural: pain, stiffness, morning aggravation.

Restlessness, better by warmth and gentle motion.

Early menopausal complaints: hot flushes, anxiety, insomnia.

Example remedies: *Rhus tox*, *Formica rufa*.

2. Syphilitic manifestations

Destructive changes in bones and cartilage.

Deformities of joints, osteophyte formation, ankylosis.

Severe nocturnal pain, worse in damp cold.

Example remedies: *Calcarea fluorica*.

3. Sycotic manifestations

Overgrowth, swelling, nodosities, effusion in synovial sacs.

Chronic stiffness with intermittent inflammatory swelling.

Obesity, sluggish metabolism, tendency to oedema.

Example remedies: *Causticum*, *Ruta*.

Methods and Materials

Study design

The present study was designed as a comparative, prospective, randomized clinical trial to evaluate the role of *Formica rufa* in comparison with other commonly prescribed homoeopathic medicines in the management of osteoarthritis among menopausal women. The study duration was 6 months, including baseline assessment, intervention, and follow-up periods. Ethical clearance was obtained prior to commencement, and informed consent was collected from all participants.

Participants

A total of [insert sample size, e.g., 50-60] menopausal women aged between 45 and 65 years, diagnosed with primary osteoarthritis of the knee according to the American College of Rheumatology (ACR) criteria, clinical

Inclusion criteria

- Postmenopausal women (≥ 12 months of amenorrhea).
- Clinical symptoms of osteoarthritis (knee pain, stiffness, reduced mobility)
- Willingness to participate and comply with follow-up.

Exclusion criteria

- Secondary osteoarthritis (trauma, infection, autoimmune).
- Severe comorbidities such as uncontrolled diabetes, hypertension, cardiac disorders, or malignancy.
- Patients on long-term steroid, HRT, or NSAID therapy.
- Advanced OA (grade IV) requiring surgical intervention.
- Any other systemic disease

Data source: Out Patient Department BVVS Homoeopathic Medical College and Hospital, Bagalkot

Grouping and intervention

Participants were randomized into two groups:

Group A (Study group): Received *Formica rufa* in appropriate potency (30C or 200C), repeated as per homoeopathic principles, depending on symptom similarity.

Group B (individualized group): Received other indicated homoeopathic remedies (*Rhus toxicodendron*, *Calcarea fluorica*, *Ruta graveolens*, *Bryonia alba*, *Causticum*) on the basis of individual case taking.

Treatment was administered for 12 weeks, with follow-up every 2 weeks.

Outcome measures

Primary and secondary outcome measures were assessed at baseline, 6 weeks, and 12 weeks:

Primary outcomes

Pain intensity: Visual Analog Scale (VAS, 0-10).

Functional disability: WOMAC Index (Western Ontario and McMaster Universities Osteoarthritis Index).

Secondary outcomes

Morning stiffness duration (minutes).

Range of motion of the knee (measured by goniometer).

Patient Global Assessment (PGA) of improvement.

Use of rescue medication (if any).

Statistical analysis

Data were entered into SPSS version [insert version].

Continuous variables (VAS, WOMAC scores) were expressed as mean \pm standard deviation (SD).

Within-group comparisons were analyzed using paired t-test (baseline vs. post-treatment).

Between-group differences were analyzed using independent t-test/ANOVA.

Categorical data were analyzed using Chi-square test.

A p-value < 0.05 was considered statistically significant.

Differentiating clinical features for remedy selection

Format: Remedies were analyzed under four aspects - action, indications, modalities, and constitutional affinity.

Study process

The study was conducted in sequential phases to ensure methodological accuracy and reliability of results.

Recruitment and screening

Menopausal women between 45-65 years of age, presenting with knee joint pain, stiffness, and functional limitation, were recruited from the Homoeopathy Outpatient Department. Each participant underwent clinical evaluation

based on American College of Rheumatology (ACR) criteria to confirm osteoarthritis. Eligibility was determined using defined inclusion and exclusion criteria.

Informed consent and baseline assessment

Written informed consent was obtained. Baseline assessment included demographic details, menopausal history, clinical symptoms, Visual Analog Scale (VAS) for pain, and WOMAC Index for functional disability.

Randomization and group allocation

Eligible participants were randomly assigned into two groups using a computer-generated randomization list:

Group A: Received *Formica rufa* in appropriate potency (30C/200C), individualized according to homoeopathic principles.

Group B: Received other indicated homoeopathic remedies (*Rhus toxicodendron*, *Calcarea fluorica*, *Ruta graveolens*, *Bryonia alba*, *Causticum*) based on symptom similarity and totality of symptoms.

Treatment protocol

Medicines were prescribed in single doses and repeated only when clinically indicated.

Follow-up visits were scheduled every 2 weeks for a period of 12 weeks.

Symptom changes, improvement, or aggravations were recorded systematically.

Follow-up and monitoring

Clinical evaluation was carried out at baseline, 6 weeks, and 12 weeks. Assessment included:

Pain score (VAS).

Functional disability (WOMAC Index).

Range of motion (measured with goniometer).

Morning stiffness and overall patient satisfaction (PGA).

Adverse effects or need for rescue medication were documented.

Outcome measures

Primary outcomes: Reduction in pain (VAS), improvement in WOMAC scores.

Secondary outcomes: Range of motion, stiffness duration, global patient assessment.

Sample remedies chosen

Rationale for inclusion: Each remedy represents a distinct pathological sphere (degeneration, fibrous tissue, bone metabolism, connective tissue, ligament weakness, and menopausal nervous-muscular complaints), allowing a comprehensive comparative study.

Formica rufa

Why? Strong affinity for joints and synovial membranes, especially in chronic OA of menopause.

Best suited for Persistent pain, stiffness, worse in cold/damp, better in warmth.

Role: Core prescription for degenerative menopausal knee OA.

Sphere of action: Joints, periarticular tissues, chronic rheumatism.

Key features

Marked stiffness and pain, especially in knees.

Pains worse from cold and damp; better from dry warmth.
Suitable for chronic degenerative joint changes in menopausal women.

Role: Acts deeply on synovial inflammation and cartilage degeneration, effective when OA pain is persistent with stiffness.

Rhus toxicodendron

Why? Classic for stiffness worse at rest, better by movement, fits many menopausal women with morning stiffness.

Best suited for: OA with “rusty hinge” joints, < cold/damp, > motion.

Role: Functional stiffness remedy can be complementary to *Formica rufa*.

Sphere of action: Fibrous tissues, tendons, ligaments, synovial membranes.

Key features

Pain worse at rest, better by motion (“rusty hinge” joints).

Aggravated in damp, cold weather.

Suited to OA with early morning stiffness that eases with activity.

Role: Useful in osteoarthritis with marked stiffness and rest-aggravated pain in menopausal women.

Calcarea fluorica

Why? Excellent for advanced cases with bony deformity, osteophytes, hard swelling.

Best suited for: Long-standing OA with visible nodal changes (Heberden’s nodes, knee osteophytes).

Role: Structural remedy addresses hardness and deformity.

Sphere of action: Bones, joints, ligaments (esp. hard bony outgrowths, exostosis, osteophytes).

Key features

Pain with hard nodes around joints.

Worse in damp weather and initial movement.

Stiffness with bony deformity.

Role: Suited for advanced OA with osteophytic changes, hard swelling, or deformities in menopausal women.

Ruta graveolens

Why? More for tendons, ligaments, and periosteal pain than true joint cartilage degeneration.

Best suited for: Menopausal OA with soreness/strain in periarticular tissues.

Role: Supportive in ligamentous weakness around joints.

Sphere of action: Periosteum, tendons, cartilage.

Key features

Pain and weakness in tendons and ligaments.

Worse on overuse, better by rest.

Stiff, sore joints with injury-like pain.

Role: OA in menopause where periarticular tissues and tendinous insertions are involved; “weakness” and soreness dominate.

Bryonia alba

Why? Suited to OA with pain aggravated by slightest movement and relieved by rest.

Best suited for: Swollen, inflamed joints; sedentary women with dryness of membranes.

Role: Inflammatory OA stage during menopause.

Sphere of action: Serous and synovial membranes.

Key features

Pain worse by slightest motion, better by rest and pressure.

Joints red, swollen, and painful.

Thirsty, irritable constitution.

Role: OA where rest relieves and movement aggravates, especially with joint swelling and dryness.

Causticum

Why? Acts well in contractures, deformity, and progressive stiffness, but less frequently first-line in pure OA.

Best suited for: Late-stage OA with deformity, weakness, and gradual disability.

Role: Chronic support remedy in advanced disabling OA.

Sphere of action: Muscles, tendons, nerves.

Key features

Contractures and stiffness in joints.

Progressive weakness and deformity.

Better in damp weather, worse in dry cold.

Role: Menopausal OA with chronic stiffness, contractures, deformities, and gradual functional decline.

Results

Comparative analysis revealed

Formica rufa is most effective in chronic, degenerative OA with synovial thickening, crepitus, and stiffness better from continued movement.

Rhus toxicodendron is valuable in acute stiffness and weather-sensitive cases where restlessness compels motion.

Ruta graveolens is preferred when ligament and tendon strain aggravates OA symptoms.

Bryonia → pain worse by movement.

Calc. fluor. → hard bony outgrowths.

Causticum → contractures & deformity

Discussion

Osteoarthritis in menopausal women presents a multifactorial challenge, combining hormonal changes, calcium deficiency, and degenerative pathology.

Formica rufa emerges as the most direct remedy for chronic OA, addressing joint degeneration with crepitus and stiffness. This emphasizes the holistic principle of homoeopathy selection based not only on pathology but also on the constitution and modalities.

Conclusion

Formica rufa is effective in chronic degenerative OA with stiffness and swelling in menopausal women.

Individualized remedies like *Rhus tox*, *Calcarea fluorica*, *Bryonia alba*, *Ruta graveolens*, *Causticum* depending on individual symptoms.

Individualization is the key to successful management, ensuring remedies are tailored according to modalities, constitution, and menopausal state.

Further clinical trials are needed to substantiate the comparative efficacy of these remedies in menopausal osteoarthritis.

Acknowledgement

I express my deepest gratitude to BVVS Homoeopathic Medical College and Hospital, Bagalkot for providing me with the opportunity and resources to carry out this study on

the Comparative Role of *Formica rufa* and Other Homoeopathic Medicine in Menopausal Women Osteoarthritis.

I am sincerely thankful to my guide and mentor, Dr. Amaresh Balaganur whose valuable guidance, encouragement, and constructive suggestions have been instrumental throughout the course of this research.

My special appreciation goes to the participants of this study, without whom this research would not have been possible. Their trust and willingness to be a part of this work are truly commendable.

References

1. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. *Arthritis Rheum.* 1998;41(8):1343-1355.
2. Lane NE, Nevitt MC, Cooper C, Pressman A, Gore R, Hochberg M, et al. Menopause, hormone replacement therapy, and osteoarthritis. *Curr Rheumatol Rep.* 2002;4(6):439-445.
3. Chopra A, Doiphode VV. Ayurvedic medicine and arthritis. *Rheumatology (Oxford).* 2002;41(8):899-904.
4. Kent JT. Lectures on homoeopathic philosophy. New Delhi: B. Jain Publishers.
5. Boericke W. Pocket manual of homoeopathic materia medica. New Delhi: B. Jain Publishers.
6. Clarke JH. A dictionary of practical materia medica. London: Homeopathic Publishing Company.
7. Phatak SR. Concise materia medica of homoeopathic remedies. New Delhi: B. Jain Publishers.
8. Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., editors. *Harrison's principles of internal medicine.* New York: McGraw-Hill.
9. Allen HC. Keynotes and characteristics with comparisons. New Delhi: B. Jain Publishers.
10. Hahnemann S. Chronic diseases, their peculiar nature and their homoeopathic cure. New Delhi: B. Jain Publishers.

How to Cite This Article

Pujari S, Balaganur A, Hooli A. Comparative role of *Formica rufa* and other homoeopathic medicines in menopausal osteoarthritis. *International Journal of Homoeopathic Sciences.* 2025;9(3):1004-1008.

Creative Commons (CC) License

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.